Carisma Therapeutics announced that the U.S. FDA has granted Fast Track designation for CT-0525, an ex vivo gene-modified autologous chimeric antigen receptor-monocyte cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARM:
- Carisma Therapeutics management to meet virtually with BTIG
- Carisma Therapeutics Grants Executive Stock Options for Retention
- Carisma Therapeutics: First patient dosed in Phase 1 clinical trial of CT-0525
- Carisma Therapeutics price target lowered to $8 from $9 at H.C. Wainwright
- Securing Success: The Crucial Role of IP Rights in Carisma Therapeutics’ Market Dominance